Substance / Medication

Sildenafil

Overview

Active Ingredient
sildenafil
RxNorm CUI
136411

Indications

Adults Clinical Studies (14) [see] Sildenafil for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening. Pediatric use information is approved for Viatris Specialty LLC’s, REVATIO (sildenafil) oral suspension. However, due to Viatris Specialty LLC’s marketing exclusivity rights, this drug product is not labeled with that information.

Labeler: Amneal Pharmaceuticals NY LLCUpdated: 2024-02-02T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Sildenafil for oral suspension is contraindicated in patients with: Warnings and Precautions (5.1) [see] Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension. Concomitant use of riociguat, a guanylate cyclase stimulator. Phos

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

55 trials linked to this intervention

55
Total Trials
13
Recruiting
16
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Sildenafil and risk of Alzheimer disease: a systematic review and meta-analysis.
Chua Wei Yu, Lim Lincoln Kai En, Wang James Jia Dong et al. · Aging (Albany NY) · 2025
PMID: 40096550Meta-AnalysisFull text (PMC)
Efficacy of sildenafil combined with statins in treating pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Zhuo Ma-Li, Xu Jin-Long, Zhang Wen et al. · Pathol Res Pract · 2025
PMID: 40716122Meta-Analysis
Perioperative sildenafil therapy in pulmonary hypertension associated with congenital cardiac disease: An updated meta-analysis.
Usmani Shajie Ur Rehman, Hasan Syed Umar, Ali Syed Hasan et al. · Asian J Surg · 2024
PMID: 38531747Meta-Analysis
Physiological Effects of Sildenafil Versus Placebo at High Altitude: A Systematic Review.
Poudel Sangeeta, Gautam Sandesh, Adhikari Purushottam et al. · High Alt Med Biol · 2024
PMID: 37751174Meta-Analysis
Preoperative Sildenafil in Pediatric Patients Undergoing Congenital Heart Surgeries: A Systematic Review and Meta-Analysis.
Fikri Yusuf Ananda, Mulia Eka Prasetya Budi, Nugroho Faris Wahyu · Semin Cardiothorac Vasc Anesth · 2023
PMID: 37844905Meta-Analysis
Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.
Shafiee Arman, Bahri Razman Arabzadeh, Teymouri Athar Mohammad Mobin et al. · BMC Gastroenterol · 2023
PMID: 37217851Meta-AnalysisFull text (PMC)
Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials.
Awad Ahmed K, Gad Eman Reda, Abdelgalil Mahmoud Shaban et al. · BMC Pediatr · 2023
PMID: 37474896Meta-AnalysisFull text (PMC)
Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Pitre Tyler, Khalid Muhammad Faran, Cui Sonya et al. · Pulm Pharmacol Ther · 2022
PMID: 35452834Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sildenafil (substance)
SNOMED CT
372572000
UMLS CUI
C0529793
RxNorm CUI
136411
Labeler
Amneal Pharmaceuticals NY LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
55
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.